Metabolic Injectables
FDA Proposes Exclusion of GLP-1s from the 503B Bulks List: Implications for Outsourcing Facilities
The U.S. Food and Drug Administration (FDA) continues to refine the regulatory framework governing compounded medications, introducing significant implications...
Read more Regulatory Updates